Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036572 (
seizures
)
80,221
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Epilepsy has many causes and comorbidities affecting as many as 4% of people in their lifetime. Both idiopathic and symptomatic epilepsies are highly heritable, but genetic factors are difficult to characterize among humans due to complex disease etiologies. Rodent genetic studies have been critical to the discovery of
seizure
susceptibility loci, including
Kcnj10
mutations identified in both mouse and human cohorts. However, genetic analyses of epilepsy phenotypes in mice to date have been carried out as acute studies in
seizure
-naive animals or in Mendelian models of epilepsy, while humans with epilepsy have a history of recurrent
seizures
that also modify brain physiology. We have applied a repeated
seizure
model to a genetic reference population, following
seizure
susceptibility over a 36-d period. Initial differences in generalized seizure threshold among the Hybrid Mouse Diversity Panel (HMDP) were associated with a well-characterized
seizure
susceptibility locus found in mice:
Seizure
susceptibility 1
Remarkably,
Szs1
influence diminished as subsequent induced
seizures
had diminishing latencies in certain HMDP strains. Administration of eight
seizures
, followed by an incubation period and an induced retest
seizure
, revealed novel associations within the
calmodulin-binding transcription activator 1
,
Camta1
Using systems genetics, we have identified four candidate genes that are differentially expressed between
seizure
-sensitive and -resistant strains close to our novel
Epileptogenesis susceptibility factor 1
(
Esf1
) locus that may act individually or as a coordinated response to the neuronal stress of
seizures
.
...
PMID:Multidimensional Genetic Analysis of Repeated Seizures in the Hybrid Mouse Diversity Panel Reveals a Novel Epileptogenesis Susceptibility Locus. 2862 84